Introduction {#s1}
============

T lymphocytes play a central role in immune defense by mounting specific responses to eliminate infections and transformed cells. To perform an immunosurveillance function, T cells continuously circulate throughout the body until they encounter specific antigen on the surface of the antigen presenting cell (APC, [Table 1](#T1){ref-type="table"}). Such contact with an APC triggers an initial activation of the T cell, which rapidly reorients its organelles and mobilizes signaling proteins to the contact site. This process is accompanied by dynamic structural and cytoskeletal changes within the T cell. An activated T cell undergoes an episode of rapid proliferation, cytokine secretion, differentiation into effector subtypes, and site-specific recruitment. These functional processes in T lymphocytes are precisely regulated and are critical for mounting an effective immune response.

###### 

A list of abbreviations used.

  **Abbreviations used**   
  ------------------------ -------------------------------------------------------------------------
  AKAP                     A-kinase anchoring protein
  APC                      Antigen presenting cell
  cAMP                     Cyclic adenosine monophosphate
  CAMSAP2                  Calmodulin regulated spectrin associated protein family member 2
  CAMSAP3                  Calmodulin regulated spectrin associated protein family member 3
  CBFA2T3                  CBFA2/RUNX1 partner transcriptional co-repressor 3
  Cdk                      Cyclin dependent kinase
  CG-NAP                   Centrosome- and Golgi-localized protein kinase N-associated protein
  CHO                      Chinese hamster ovary
  CK1δ/ε                   Casein kinase 1 delta/epsilon
  CRISPR                   Clustered regularly interspaced short palindromic repeats
  EB1                      End-binding protein 1
  GM130                    130 KDa cis-Golgi matrix protein
  GTP                      Guanosine triphosphate
  HIV                      Human immunodeficiency viruses
  ICAM-1                   Intercellular adhesion molecule 1
  IL                       Interleukin
  IS                       Immune synapse
  JC virus                 John Cunningham virus
  KCNE1                    Potassium voltage-gated channel subfamily E regulatory subunit 1
  Kiz                      Kizuna
  LAT                      Linker for activation of T cells
  LFA-1                    Lymphocyte function-associated antigen 1
  MAPRE1                   Microtubule associated protein RP/EB family member 1
  MMG8                     Myomegalin variant 8
  MTCL1                    Microtubule cross-linking factor 1
  MTOC                     Microtubule organizing center
  NFAT                     Nuclear factor of activated T cells
  NFκB                     Nuclear factor kappa B
  PACT                     Pericentrin-AKAP450 centrosomal targeting
  PDE4D                    Phosphodiesterase 4D
  PKA                      Protein kinase A
  PKC                      Protein kinase C
  PKN                      Protein kinase N
  PLCγ1                    Phospholipase C gamma 1
  Plk1                     Polo-like kinase 1
  PP1                      Protein phosphatase 1
  PP2A                     Protein phosphatase 2A
  PR130                    Serine/Threonine-protein phosphatase 2a 72/130 KDa regulatory subunit B
  RAPGEF2                  Rap guanine nucleotide exchange factor 2
  RUNX1T1                  RUNX1 partner transcriptional co-repressor 1
  siRNAs                   Small interfering RNA
  TCR                      T cell receptor
  TGFβ                     Transforming growth factor beta
  TUBGCP                   Tubulin gamma complex associated protein
  γ-TuRC                   Gamma tubulin ring complex

Multiple stages of T cell functions, such as activation, differentiation, conjugate formation with APCs, homing and motility are crucially regulated by protein kinases ([@B1], [@B2]). As members of the kinase superfamily are widely distributed within cells and often have broad substrate specificity, a crucial element in signal transduction is local control of substrate specificity ([@B3], [@B4]). How is an individual kinase directed to connect with a single substrate or multiple components of a pool of downstream substrates? In some cases, kinase specificity is achieved by influencing substrate recognition. In this context, a class of proteins collectively known as "adaptor, anchoring and scaffolding proteins," have emerged as important mediators of signal transduction processes ([@B5], [@B6]). These proteins form specialized docking platforms that facilitate the formation of multicomponent signaling complexes, maintain static protein-protein interactions, position their kinase cargo in proximity to a subset of substrates, organize processes and components of protein kinase cascades and thus streamline cell signaling responses ([@B6]--[@B13]). In T lymphocytes, these signal-organizing proteins allow signals to be transduced with precision in response to molecular instructions from the cell surface ([@B14]--[@B16]). Most importantly, these anchoring/adaptor proteins facilitate the phosphorylation and dephosphorylation of protein kinases, including trans- and auto-phosphorylations, which are important for the kinases to gain catalytically competent conformation in order to respond to intra- and/or extra-cellular signals ([@B16], [@B17]). Anchoring/adaptor proteins thus control numerous cellular processes in T lymphocytes, including cell fate decisions, activation, differentiation and various stages of development and functions ([@B16]--[@B19]). Herein, we review the involvement of such an anchoring protein "Centrosome and Golgi localized protein kinase N (PKN)-Associated Protein" (CG-NAP), also known as A-Kinase Anchoring Protein 450 (AKAP450) ([@B20]--[@B22]), in the regulation of protein kinase dynamics and functional outcomes in T cells.

A-Kinase Anchoring Proteins (AKAPs) {#s2}
===================================

AKAPs are a family of ubiquitously expressed structurally diverse signal-organizing proteins with tissue/cell-type specific expression patterns in human. So far, 41 AKAPs encoded by 41 genes have been experimentally validated in human cells and tissues ([@B8], [@B23]) ([Table 2](#T2){ref-type="table"}). Nine different AKAPs have been described in human T lymphocytes -- AKAP1, AKAP2, AKAP5, AKAP8, AKAP9 (known as CG-NAP), AKAP11, Ezrin, RUNX1T1, and RUNX1T3 ([@B24]--[@B26]) and at least eight AKAPs with apparent molecular masses of 60, 75, 95, 120, 165, 190, 245, and 275 kDa were detected in mouse T lymphocytes ([@B27]); however, their involvements in the regulation of immune functions remain poorly understood.

###### 

A list of AKAP family proteins.

  **S.N**.   **AKAPs**   **Name**                                                                 **Synonyms**                                                                                                                                                **HGNC ID (gene)**   **Chromosome**
  ---------- ----------- ------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------- ---------------------
  1\.        AKAP1       A-kinase anchoring protein 1                                             PRKA1, AKAP121, AKAP149, SAKAP84, S-AKAP84, AKAP84, D-AKAP1, PPP1R43, TDRD17                                                                                HGNC:367             17q22
  2\.        AKAP2       A-kinase anchoring protein 2                                             PRKA2, AKAP-KL, KIAA0920, DKFZp564L0716, MISP2                                                                                                              HGNC:372             9q31.3
  3\.        AKAP3       A-kinase anchoring protein 3                                             FSP95, SOB1, AKAP110, CT82                                                                                                                                  HGNC:373             12p13.32
  4\.        AKAP4       A-kinase anchoring protein 4                                             p82, hAKAP82, AKAP82, Fsc1, HI, CT99                                                                                                                        HGNC:374             Xp11.22
  5\.        AKAP5       A-kinase anchoring protein 5                                             AKAP75, AKAP79                                                                                                                                              HGNC:375             14q23.3
  6\.        AKAP6       A-kinase anchoring protein 6                                             KIAA0311, mAKAP, AKAP100, PRKA6, ADAP6                                                                                                                      HGNC:376             14q12
  7\.        AKAP7       A-kinase anchoring protein 7                                             AKAP18, AKAP15                                                                                                                                              HGNC:377             6q23.2
  8\.        AKAP8       A-kinase anchoring protein 8                                             AKAP95, DKFZp586B1222                                                                                                                                       HGNC:378             19p13.12
  9\.        AKAP9       A-kinase anchoring protein 9                                             KIAA0803, AKAP350, AKAP450, CG-NAP, YOTIAO, HYPERION, PRKA9, MU-RMS-40.16A, PPP1R45, LQT11                                                                  HGNC:379             7q21.2
  10\.       AKAP10      A-kinase anchoring protein 10                                            D-AKAP2, PRKA10, MGC9414                                                                                                                                    HGNC:368             17p11.2
  11\.       AKAP11      A-kinase anchoring protein 11                                            KIAA0629, AKAP220, PRKA11, FLJ11304, DKFZp781I12161, PPP1R44                                                                                                HGNC:369             13q14.11
  12\.       AKAP12      A-kinase anchoring protein 12                                            AKAP250, SSeCKS, gravin                                                                                                                                     HGNC:370             6q25.1
  13\.       AKAP13      A-kinase anchoring protein 13                                            LBC, Ht31, BRX, AKAP-Lbc, c-lbc, PROTO-LB, HA-3, ARHGEF13                                                                                                   HGNC:371             15q25.3
  14\.       AKAP14      A-kinase anchoring protein 14                                            AKAP28                                                                                                                                                      HGNC:24061           Xq24
  15\.       AKAP17A     A-kinase anchoring protein 17A                                           CXYorf3, SFRS17A, XE7, XE7Y, DXYS155E, MGC39904, 721P, CCDC133                                                                                              HGNC:18783           Xp22.33 and Yp11.32
  16\.       AKAP17BP    A-kinase anchoring protein 17B, pseudogene                               AKAP16B, AKAP16BP                                                                                                                                           HGNC:38514           Xq24
  17\.       ACBD3       Acyl-CoA binding domain containing 3                                     GOLPH1, GOCAP1, GCP60, PAP7                                                                                                                                 HGNC:15453           1q42.12
  18\.       ARFGEF2     ADP ribosylation factor guanine nucleotide exchange factor 2             BIG2                                                                                                                                                        HGNC:15853           20q13.13
  19\.       CHD8        Chromodomain Helicase DNA Binding Protein 8                              HELSNF1, Helicase with SNF2 Domain 1, AUTS18, Duplin, KIAA1564                                                                                              HGNC:20153           14q11.2
  20\.       CMYA5       Cardiomyopathy associated 5                                              C5orf10, SPRYD2, DKFZp451G223, TRIM76                                                                                                                       HGNC:14305           5q14.1
  21\.       C2orf88     Chromosome 2 open reading frame 88                                       MGC13057, smAKAP                                                                                                                                            HGNC:28191           2q32.2
  22\.       EZR         Ezrin                                                                    VIL2, Villin 2, P81, Cytovillin                                                                                                                             HGNC:12691           6q25.3
  23\.       GSKIP       GSK3B Interacting Protein                                                C14orf129                                                                                                                                                   HGNC:20343           14q32.2
  24\.       ITGA4       α4 integrin                                                              CD49D                                                                                                                                                       HGNC: 6140           2q31.3
  25\.       MAP2        Microtubule associated protein 2                                         MAP2A, MAP2B, MAP2C                                                                                                                                         HGNC:6839            2q34
  26\.       MSN         Moesin                                                                   IMD50, HEL70, Membrane-Organizing Extension Spike Protein                                                                                                   HGNC: 7373           Xq12
  27\.       MYO7A       Myosin VIIA                                                              USH1B, DFNB2, DFNA11, SRD2                                                                                                                                  HGNC:7606            11q13.5
  28\.       MYRIP       Myosin VIIA and Rab interacting protein                                  DKFZp586F1018, exophilin-8, MyRIP, SLAC2-C, SLAC2C                                                                                                          HGNC:19156           3p22.1
  29\.       NBEA        Neurobeachin                                                             KIAA1544, BCL8B, FLJ10197, LYST2                                                                                                                            HGNC:7648            13q13.3
  30\.       NF2         Neurofibromin 2                                                          merlin, ACN, SCH, BANF                                                                                                                                      HGNC:7773            22q12.2
  31\.       OPA1        Optic Atrophy Protein 1                                                  MyRIP, Optic Atrophy Protein 1, OPA1 Mitochondrial Dynamin Like GTPase, NTG, NPG, BERHS, LargeG, MTDPS14, KIAA0567, Dynamin-Like Guanosine Triphosphatase   HGNC: 8140           3q29
  32\.       PDE4DIP     Phosphodiesterase 4D Interacting Protein                                 MMGL, CMYA2, Myomegalin, Cardiomyopathy-Associated Protein                                                                                                  HGNC:15580           1q21.2
  33\.       PIK3CG      Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma   P110γ, PI3Kγ, PI3CG, P120-PI3K                                                                                                                              HGNC:8978            7q22.3
  34\.       RAB32       Ras-Related Protein Rab-32                                               Rab32                                                                                                                                                       HGNC:9772            6q24.3
  35\.       RSPH3       Radial Spoke Head 3                                                      RSP3, RSHL2                                                                                                                                                 HGNC:21054           6q25.3
  36\.       RUNX1T1     RUNX1 Partner Transcriptional Co-Repressor 1                             AML1T1, CBFA2T1, MTG8                                                                                                                                       HGNC:1535            8q21.3
  37\.       RUNX1T3     RUNX1 Partner Transcriptional Co-Repressor 3                             CBFA2T3, ETO2, HMTG16, MTG8-Related Protein 2, MTG16, MTGR2, ZMYND4                                                                                         HGNC:1537            16q24.3
  38\.       SPHKAP      SPHK1 interactor, AKAP domain containing                                 SKIP                                                                                                                                                        HGNC:30619           2q36.3
  39\.       SYNM        Synemin                                                                  DMN, KIAA0353, SYN                                                                                                                                          HGNC:24466           15q26.3
  40\.       TNNT2       Troponin T2                                                              c-troponinT, TnTC, CMPD2, LVNC6, CMD1D, CMH2                                                                                                                HGNC:11949           1q32.1
  41\.       WASF1       WAS protein family member 1                                              WAVE1, SCAR1, KIAA0269, WAVE                                                                                                                                HGNC:12732           6q21

Although members of the AKAP family differ greatly in their amino-acid sequences, structures, intracellular localizations and repertoire of protein binding partners, they all interact directly with the regulatory subunits of the protein kinase A (PKA) ([@B28]--[@B33]). However, the mechanism by which molecular interactions between specific AKAPs and PKA regulate normal and pathological signaling in human cells/tissues is just beginning to be understood.

AKAPs, through association with PKA, are involved in regulating T cell functions through the ubiquitous second messenger molecule cAMP ([@B34]--[@B36]), which controls cellular processes dictated by cell surface receptor-induced signaling ([@B37]--[@B39]). The interactions between AKAPs and PKA are complex as there are four distinct regulatory subunit isoforms of PKA -- RIα, RIβ, RIIα, and RIIβ ([@B7]). These subunits differ in tissue distribution, cAMP sensitivity and AKAP-mediated localization, which fine-tune molecular signals depending on when and where PKA activity is applied ([@B40]). Most AKAPs bind to the RII isoform and a few dual-specific AKAPs can also interact with the RI isoform ([@B33], [@B41]). In addition, there are recent examples of RI selective AKAPs ([@B42]--[@B44]). Furthermore, most cell types simultaneously express multiple AKAPs (e.g., human T cells express at least 9 different AKAPs) ([@B24]--[@B26]).

It should be noted that the PKA-binding module of AKAPs denotes only one facet of their regulatory control. Apart from their interactions with PKA, AKAPs also interact with other downstream proteins and signaling enzymes, including protein kinase C (PKC) isoforms and PKN, protein phosphatases, phosphodiesterases, small GTPases ([@B8]) and substrates to integrate a diverse range of signals within distinct multivalent assemblies. The spatiotemporal interactions between enzymes and target substrates are important in the regulation of T cell functions as well as in the maintenance of T cell homeostasis ([@B27]).

CG-NAP: A Giant Member of the AKAP Protein Family {#s3}
=================================================

CG-NAP is a member of the AKAP family, prominently expressed in human T cells, in which this giant protein predominantly localizes to the centrosome ([@B20]). The human *CG-NAP* gene is located on the chromosome 7q21-22 and contains at least 50 exons ([@B45]--[@B47]). A total of 16 splice variants have been identified in the *CG-NAP* gene ([Table 3](#T3){ref-type="table"}). The cDNA derived from the *CG-NAP* gene contains 11.7 kb open reading frame coding the 3899 amino acid protein with a calculated molecular mass of 451.8 kDa ([@B45]). The CG-NAP protein has several stretches of coiled-coil structures and four leucine zipper-like motifs ([Figure 1](#F1){ref-type="fig"}) and these structural motifs are involved in interactions with other signaling proteins (e.g., PKA, PKN and PKC isoforms) ([@B45]). Amino acid sequence comparison using BLAST analysis shows that regions of human CG-NAP share high homology with the rabbit AKAP120 and limited homology to the mouse pericentrin ([@B48]--[@B50]).

###### 

A list of 16 splice variants (transcripts) of the CG-NAP gene in human.

  **S.N**.   **Name**    **Transcript ID**   **bp**   **Protein**   **Biotype**       **UniProt**
  ---------- ----------- ------------------- -------- ------------- ----------------- --------------------------
  1\.        AKAP9-201   ENST00000356239.7   12471    3907aa        Protein coding    [Q99996](Q99996)
  2\.        AKAP9-203   ENST00000359028.6   12247    3910aa        Protein coding    [A0A0A0MRF6](A0A0A0MRF6)
  3\.        AKAP9-202   ENST00000358100.6   10309    3126aa        Protein coding    [A0A0A0MRE9](A0A0A0MRE9)
  4\.        AKAP9-216   ENST00000619023.4   6006     1637aa        Protein coding    [A0A087WX84](A0A087WX84)
  5\.        AKAP9-204   ENST00000394534.6   5652     1769aa        Protein coding    [H7BYL6](H7BYL6)
  6\.        AKAP9-206   ENST00000435423.1   1904     318aa         Protein coding    [H0Y6Q0](H0Y6Q0)
  7\.        AKAP9-213   ENST00000491695.1   1389     282aa         Protein coding    [A0A2R8Y590](A0A2R8Y590)
  8\.        AKAP9-205   ENST00000394564.5   1356     314aa         Protein coding    [Q6PJH3](Q6PJH3)
  9\.        AKAP9-207   ENST00000438114.1   696      232aa         Protein coding    [H7BZV6](H7BZV6)
  10\.       AKAP9-214   ENST00000493453.1   6020     No protein    Retained intron   --
  11\.       AKAP9-211   ENST00000487258.5   3983     No protein    Retained intron   --
  12\.       AKAP9-208   ENST00000463118.1   891      No protein    Retained intron   --
  13\.       AKAP9-212   ENST00000487692.1   869      No protein    Retained intron   --
  14\.       AKAP9-215   ENST00000493976.1   724      No protein    Retained intron   --
  15\.       AKAP9-209   ENST00000484815.1   671      No protein    Retained intron   --
  16\.       AKAP9-210   ENST00000486313.1   584      No protein    lncRNA            --

*The list was prepared from the Ensembl database using the HGNC ID HGNC:379*.

![An illustration of the domain organization of the CG-NAP. Modular structures of coiled-coil (CC1, CC2, and CC3), 4 Leucine Zippers and the PACT domain are shown schematically.](fimmu-10-02642-g0001){#F1}

CG-NAP/Protein Kinase Interactions in T Cells {#s4}
=============================================

The modular architecture of CG-NAP brings many protein kinases and their substrates in proximity within a cell and thus regulates the rate and magnitude of cytoplasmic catalysis. Since its initial characterization in 1999 ([@B45]) and the establishment of its role in regulating intracellular membrane trafficking and cell cycle progression ([@B51]), several interacting partners of CG-NAP have been identified in various cell types, including T lymphocytes ([Figure 2](#F2){ref-type="fig"}).

![An illustration showing T cell CG-NAP as an anchoring protein that provides a docking platform for several kinases and their substrates. In particular, the Golgi-localized CG-NAP interacts with PKA, PKN, PKC isoforms, dynein, pericentrin, γ-tubulin, MTCL1, PP1, PP2A, CK1, calmodulin, CIP4, cyclin E, and Cdk2 and regulates T cell functions, including activation, proliferation, IS formation and migration.](fimmu-10-02642-g0002){#F2}

Previous studies using co-immunoprecipitation approaches and deletion mutants to identify CG-NAP interacting partners revealed that CG-NAP functions as an anchoring molecular platform for protein kinases, including PKA ([@B45]). Using a yeast two-hybrid screening system, it has been demonstrated that CG-NAP interacts with the N-terminus of PKN ([@B45]). In addition, CG-NAP associates with the catalytic subunit of protein phosphatase 1 (PP1) ([@B45]), protein phosphatase 2A (PP2A) through its regulatory B subunit PR130 ([@B45]), casein kinase 1 delta and epsilon (CK1δ/ε) ([@B52], [@B53]), PKC isozymes (PKCβ, PKCδ, PKCε, PKCθ) ([@B21], [@B54]), calmodulin ([@B55]), the γ-tubulin ring complex (γ-TuRC) comprising of γ-tubulin, tubulin gamma complex associated proteins 2, 3, 4, 5 and 6 (TUBGCP2, TUBGCP3, TUBGCP4, TUBGCP5, and TUBGCP6) ([@B55], [@B56]), dynein/dynactin ([@B57]), Cdc42-interacting protein 4 (CIP4) ([@B58]), Ran ([@B59]), phosphodiesterase 4D (PDE4D) ([@B45], [@B60]), cyclin E/cyclin-dependent kinase (Cdk) 2 ([@B61]) and Golgin A2/GM130 ([@B62]) in various cell types ([Figure 2](#F2){ref-type="fig"}). In cultured epithelial cells, CG-NAP forms a pericentrosomal complex with the EB1-binding-myomegalin protein complex and recruits calmodulin regulated spectrin-associated protein family member 2 and 3 (CAMSAP2 and CAMSAP3) and microtubule-associated protein RP/EB family member 1 (MAPRE1) to the Golgi ([@B55], [@B63]--[@B66]). Studies using various cell-types, including human T lymphocytes, further elucidate a role of CG-NAP in microtubule nucleation ([@B20], [@B56], [@B67]). These binding interactions with multiple proteins suggest a dynamic complexity in the active functions of CG-NAP.

In the context of T lymphocyte functions, crucial roles for CG-NAP have been demonstrated as (i) a component of the LFA-1-induced signaling complex, (ii) a mediator of T cell/APC immune synapse (IS) formation, (iii) an organizer of centrosomal re-localization, and *iv*) a facilitator of cytoskeletal rearrangement and motility ([@B20]--[@B22]). The LFA-1 β2 integrin plays multiple roles in the functioning of T lymphocytes, including migration to sites of inflammation/infection, proper functioning of the IS and functional programming for effector differentiation. In consequence, LFA-1-induced signals are critical in the pathogenesis of inflammatory diseases, such as psoriasis ([@B68]), and infectious diseases, including human immunodeficiency viruses (HIV) ([@B69]--[@B71]), Hepatitis C ([@B72], [@B73]) and John Cunningham (JC) virus ([@B74]). An active involvement of CG-NAP in mediating LFA-1 signaling suggests its potential implications for the above and other T cell-dependent diseases.

In prior studies, we have demonstrated that CG-NAP is an important component of the LFA-1 signaling complex for T lymphocyte migration ([@B20], [@B21]). These studies established that CG-NAP is expressed in T lymphocytes at the centrosome at rest and distributed both at the centrosome and along the trailing microtubules during migration ([@B20], [@B21]). CG-NAP co-immunoprecipitates with LFA-1 in activated migrating T cells ([@B21]). PKC isoforms, including PKCβ and PKCδ, also interact with CG-NAP in motile T cells ([@B21]). Hence, we concluded that the migratory signals in T lymphocytes induce the assembly of a multi-molecular protein complex involving CG-NAP, which serves as one of the docking platforms for PKCβ and PKCδ isoforms ([@B21]). PKCβ regulates LFA-1-mediated locomotion of activated T cells ([@B75]); whereas, PKCδ plays a critical role in TCR-induced negative regulation of IL-2 cytokine production and T cell proliferation ([@B76]).

Studies using cultured fibroblast cells demonstrated a direct association between CG-NAP and immature non- or hypo-phosphorylated PKCε at the Golgi and around the centrosome ([@B54]). Depending on environmental cues and upon phosphorylation, PKCε dissociates from the CG-NAP complex as a "mature" enzyme, which actively responds to second messenger signals ([@B54]). In human T cells, this PKC isoform regulates a diverse range of biological functions. In particular, PKCε modulates the TCR-associated signaling complex for T cell activation and cytokine secretion ([@B77], [@B78]), proliferation ([@B79]), sensitivity to TGFβ ([@B79]), development ([@B80]), gene expression ([@B80]), and survival ([@B81], [@B82]). PKCε directly activates the NFκB/NFAT/AP1 pathway in T cells leading to the up-regulation of IL-2 receptor expression and an increase in IL-2 production ([@B83], [@B84]). The LFA-1 signal for T cell migration activates PKCε, which phosphorylates the Rab GTPase Rab5a on Thr7, triggering a molecular cascade leading to the activation of the Rac1 protein and actin cytoskeletal rearrangements in motile T cells ([@B85]). Further studies are required to determine whether CG-NAP plays a role in the dynamic coordination of PKCε activities in human T cells.

CG-NAP/Kinase Interactions in T Cells at the Immune Synapse (IS)
----------------------------------------------------------------

Upon recognition of specific antigen on APCs and TCR engagement, a T cell undergoes a series of structural and molecular changes to form a flattened contact site, termed the "IS" ([@B86]). Within few seconds of T cell/APC contact, TCR signaling is triggered *via* an array of phosphorylation and de-phosphorylation cascades of membrane-proximal and -distal signaling elements. Within few minutes, the T lymphocyte rapidly reorients its cellular content to the intercellular contact zone. In particular, the stimulated T cell repositions its centromere from the uropod to the synapse at the contact site and dynamically orients cytoskeletal systems that allow asymmetric segregation of signaling and adhesive proteins toward the APC contact ([@B87]). This centrosomal polarization is important for the directional movement of recycling TCRs to the IS ([@B88]) and the positioning of the T cell secretory vesicles toward the APC ([@B89]). These molecular processes facilitate the polarized secretion of cytokines and cytolytic factors toward the bound target cell for effector immune responses (e.g., cell-mediated cytotoxicity and target cell destruction) ([@B90]), while preventing undesired bystander effects on neighboring cells. A single T lymphocyte is thus able to eliminate multiple target cells consecutively by integrin-mediated adhesion, rapid rearrangement of contacts and simultaneous formation of stimulatory and lytic synapses with defined central and peripheral signaling platforms. Moreover, the IS facilitates cell-to-cell communication between the T cell and the APC through exosomes and microvesicles ([@B91], [@B92]). After several hours of contact, T cell undergoes functional activation ([@B93]), and eventually differentiates to effector or memory T cells.

In the context of IS formation, CG-NAP coordinates dynamic interactions between protein kinases and their substrates at the centrosome in T cells. It colocalizes with a range of signaling molecules with implications for both the central supramolecular activation cluster (c-SMAC), which includes the TCR/CD3 complex and various costimulatory receptors, and the peripheral supramolecular activation cluster (p-SMAC) that incorporates LFA-1 ([@B22]). Functional consequences of CG-NAP loss in T cells during the IS formation, either by overexpression of a dominant-negative form or siRNA-mediated knockdown, include (i) impaired conformational activation and positioning of LFA-1 at the IS, (ii) defective segregation of LFA-1 at the p-SMAC ring, (iii) impaired LFA-1-associated signaling, (iv) reduced expression of the TCR CD3ϵ chain with decreased activation and clustering of TCR at the IS, (v) reduced phosphorylation of CD3ζ (Y83) in the TCR/CD3 complex, (vi) impaired recruitment of PKCθ to the IS, (vii) diminished phosphorylation of the phospholipase C gamma 1 (PLC-γ1), (viii) reduced activation of intracellular adaptor proteins, including the linker for activation of T cells (LAT) and Vav1, (ix) reduced phosphorylation of ERK1/2, (x) delocalization of the centrosome, (xi) defects in the translocation of microtubule organizing center (MTOC) toward the IS, and (xii) diminished production of IL-2 ([@B22]). The PKCθ isoform, PLC-γ1, ERK1/2, Vav1, and LAT play critical roles in TCR signaling. For example, activation of the TCR triggers PKCθ-mediated phosphorylation of the Rap guanine nucleotide exchange factor 2 (RAPGEF2) at Ser960, which regulates the adhesiveness of LFA-1 to its ligand ICAM-1 *via* Rap1 ([@B94]). Essential roles of PKCθ in regulating TCR-induced NFκB activation in mature thymocytes, inducible gene expression program in T cells, up-regulation and clustering of the LFA-1 on the T cell surface, adhesion capacity of T cells, effector T cell functions and protection from T cell-mediated autoimmune reactions have been documented ([@B80], [@B95]--[@B97]). An impaired PLC-γ1 activation in CG-NAP depleted T cells would impair diacylglycerol production, which is important for dynein function and MTOC translocation ([@B22]). TCR-induced phosphorylation of both LAT and Vav1 is critical for the functioning of the c-SMAC complex ([@B22]).

In the context of cytoskeletal reorganization at the IS, CG-NAP facilitates microtubule nucleation at the centrosome and non-centrosomal regions in human T cells ([@B20]). It coordinates PKA-mediated phosphorylation of dynein in motile T cells ([@B20]), which is crucial for centrosome repositioning at the IS ([@B87], [@B98]). Following APC/T cell contact, CG-NAP interacts with the kinase CK1δ that phosphorylates the microtubule plus-end binding protein EB1, which increases microtubule growth speeds ([@B99]) and has consequences for the IS. For example, T cell cytoskeletal remodeling elicits the APC to mobilize its intercellular adhesive molecules (ICAM-1 and−3) and subsequently the MHC-II molecules at the IS ([@B100]). Moreover, CG-NAP loss in human T cells impairs actin polymerization ([@B22]), which is crucial for the stabilization of APC/T cell contact at the IS ([@B101]).

CG-NAP mediates the activation of Aurora A protein kinase in human T cells ([@B102]), which is crucial for regulating signaling downstream of the TCR, such as activation of the Lck kinase and opening of the Ca^2+^ release-activated channels (CRAC)---both key signals involved in antigen-dependent T cell activation and in IS formation. Interestingly both knockdown and over-expression of CG-NAP significantly inhibit IL-2 secretion ([@B22]), suggesting multiple overlapping effects.

Thus, T cell CG-NAP contributes to the formation and maintenance of IS by serving as an intracellular scaffold for kinases and facilitating the organization and activation of receptor molecules.

CG-NAP/Kinase Interactions in T Cell Activation and Proliferation
-----------------------------------------------------------------

The processes of T cell activation, proliferation and effector functions require several independent but coordinated molecular events initiated by TCR engagement ([@B103]). According to the clonal selection theory of adaptive immunity, the activation of a single lymphocyte clone provides sufficient function for an immediate immune response (i.e., proliferation of effector cells), as well as the regenerative capacity to maintain the selected lineage (i.e., development and differentiation of memory cells). In this context, CG-NAP is potentially involved in T cell proliferation and clonal expansion. While a direct role of CG-NAP in cell proliferation and cell cycle regulation has been identified in other cell types ([@B51], [@B61], [@B104]), further studies are required to dissect this role in T lymphocytes. Nonetheless some potential interactions may be inferred. For example, CG-NAP-depleted Chinese hamster ovary (CHO) cells and HeLa cells over-expressing C-terminus CG-NAP are arrested at the G1 stage of cell-cycle followed by the induction of apoptosis in these cells ([@B51], [@B61], [@B104]). It has been shown in CHO cells that CG-NAP, by anchoring cyclin E/Cdk2 to the centrosome, drives centrosomal amplification and cell cycle progression ([@B61]). Further studies are required to determine whether CG-NAP-cyclin/Cdk complexes are involved in T cell proliferation.

At the centrosome, CG-NAP interacts with the centrosomal protein 72 kDa (Cep72) ([@B105]) and recruits the Kizuna (Kiz) protein, which is phosphorylated by the polo-like kinase 1 (Plk1) ([@B106]). The phosphorylation of Kiz enhances its association with the CG-NAP interacting protein, pericentrin ([@B106]). This association galvanizes the pericentriolar material, facilitates microtubule nucleation on the centrosome and allows for tubulin polymerization at the plus-end of the microtubules ([@B107]). CG-NAP associates with the dynein/dynactin motor complex and together with kendrin/pericentrin, anchors γ-TuRC at the centrosome through binding to its TUBGCP2 and/or TUBGCP3 subunits at the amino terminal regions ([@B55]). It provides new nucleation sites for *de novo* microtubule polymerization ([@B55], [@B67], [@B108]), which is important for cell cycle progression and proliferation of T lymphocytes. While many components of these interactions have been identified in T cells, further studies are required to determine the precise mechanisms whereby CG-NAP can regulate proliferation in human T cells.

CG-NAP also plays a crucial role in the regulation of endosomal trafficking of the TCR and is required for the effective re-stimulation of T cells ([@B109]). CG-NAP-dependent signaling and endosomal trafficking are important for the retention of T cells at sites of inflammation in mice ([@B109]). However, the viability of CG-NAP-knockout mice and the normal T cell counts in mice with conditional deletion of CG-NAP ([@B109]) suggest that CG-NAP may largely be dispensable or redundant for the maintenance of the resting T cell complement in the mouse. Loss of CG-NAP function in T cells would thus impair their sustained activation and have immunological consequences ([@B109]).

It is now clear that repeated and transient contacts of effector T cells with APCs are needed to functionally activate T lymphocytes in tissues. This suggests that signal integration between successive contacts is necessary to achieve activation. In contrast, the interactions between naïve T cells and DCs in the lymph node are relatively less dynamic and, typically, such interactions last for several hours ([@B110], [@B111]). It has also been speculated that the mechanisms of T cell activation at inflammation sites may vary from the primary activation of naïve T cells in lymph nodes ([@B109]). These tissue-specific differences in T cell activation may explain why depletion of CG-NAP does not significantly affect baseline T cell presence and differentiation in lymphoid tissues but may significantly impact T cell re-activation under suboptimal antigen-presenting conditions, such as re-activation in inflamed non-lymphoid tissue ([@B109]). Nevertheless, it has now been established that CG-NAP interacts with kinases (such as PKCβ, PKCδ, PKCε, PKCθ) ([@B21], [@B54]) and protein phosphatases (such as PP1, PP2A) ([@B45]) and transduces important signals *via* TCR ([@B22]) to regulate tissue-specific T cell activation and proliferation.

CG-NAP/Kinase Interactions in T Cell Migration
----------------------------------------------

The recruitment of T cells to the tissue sites of infection or inflammation is critical to an effective immune response. Stimulated T lymphocytes leave lymphatic tissue and search the periphery for infected or transformed cells. When a T lymphocyte encounters an APC or a transformed cell, it mounts a specific immune response in a highly controlled manner. Blockade of the multi-step process of T cell motility can impair immune reactions, while uncontrolled migration can contribute to the development of autoimmunity.

In one pathway, T cell motility is dependent on the interactions between the T cell integrin LFA-1 and its ligand ICAM-1, which is expressed on endothelial surfaces during inflammation ([@B112]). LFA-1 engagement triggers a plethora of signaling cascades causing dynamic phosphorylation/de-phosphorylation of substrates by kinases and phosphatases and formation of macromolecular signaling complexes that culminate in cytoskeletal remodeling and T cell motility ([@B112]). CG-NAP is an integral component of these LFA-1-induced multi-molecular complexes and can serve to link the centrosome, microtubules and kinases, critical to the polarization and migration of T cells ([@B5], [@B20], [@B21]).

In human T lymphocytes, CG-NAP predominantly localizes in close proximity to the centrosome and the Golgi ([@B20]). This Golgi localization of CG-NAP is disrupted by microtubule depolarization ([@B20]). In HeLa-Kyoto cells, CG-NAP was found to recruit the microtubule cross-linking factor 1 (MTCL1), a molecule which crosslinks and stabilizes non-centrosomal microtubules to the Golgi membranes ([@B113]). Hence, we hypothesize a potential role of CG-NAP/MTCL1 interactions in T cell motility, a process which requires further investigation. Furthermore, as an AKAP, CG-NAP interacts with PKA and this complex consequently phosphorylates centrosomal proteins pericentrin and dynein in motile T cells ([@B20]). Dynein plays a crucial role in MTOC repositioning, cytoskeletal organization and the movement and processes of signaling complexes during T cell activation and motility ([@B114], [@B115]). In addition to PKA, several other kinases and phosphatases, including CK1, PKC, PP1 and PP2A, phosphorylate and dephosphorylate dynein in various cell types ([@B116], [@B117]) and all these enzymes are known to be anchored to the CG-NAP ([@B45], [@B52], [@B53]).

The functional significance of CG-NAP/kinase interactions for T cell motility is further underscored by the finding that the association between CG-NAP and LFA-1-induced signaling complex is greatly reduced when T cells are maintained at low temperature conditions ([@B21]). These data suggest a potential link between CG-NAP/kinase interactions and metabolic pathways in motile T cells. T cells overexpressing the C-terminal (aa 3699-3796) mutant form of CG-NAP fail to polarize and migrate ([@B21]). This CG-NAP C-terminus region contains the PACT (pericentrin-AKAP450 centrosomal targeting) domain, which binds additional proteins ([@B50]). For example, calmodulin binds to the C-terminus of CG-NAP in a calcium-independent manner ([@B50]). In addition, CG-NAP interacts with PKCβ and PKCδ ([@B21]), a process critical for signal transduction in motile T cells ([@B75], [@B118]). While *in vitro* knockdown of CG-NAP in human T cells significantly inhibited T cell migration and chemotaxis ([@B20]), no major impact of CG-NAP depletion on T cell motility was observed in T cell-specific CG-NAP knockout mice ([@B109]). The discrepancy between these findings could be attributed to the different model systems and experimental conditions.

It has been shown that the intracellular distribution of CG-NAP in LFA-1-stimulated motile T cells is different from that in cells stimulated to migrate through interactions with fibronectin ([@B21]). These data suggest that CG-NAP plays a unique role in β2 integrin-mediated T cell motility and may not have a similar role in adhesion and motility induced *via* different integrin families, such as, the β1 integrin. It has also been demonstrated that LFA-1-induced macromolecular signaling assemblies bring together molecules involved in intracellular transport and secretion. For example, LFA-1-induced formation of CG-NAP/kinase interactome containing PKCβ is crucial for T cell IL-2 production ([@B21]).

Microtubules are prominent elements of the cytoskeleton and dynamic cytoskeletal remodeling is essential for T cell motility. In addition to the cellular microtubule arrays emanating from the centrosome or the MTOC, secondary networks exist, in which microtubules are not anchored to the centrosome. While non-centrosomal microtubules are known to be present in differentiated cells (e.g., neurons, skeletal muscles, and epithelial cells), a recent report has demonstrated non-centrosomal microtubules emanating from CG-NAP in motile T cells ([@B20]). GapmeR-mediated knockdown of CG-NAP ([@B119]) disrupted both the centrosomal and non-centrosomal microtubule nucleation and inhibited post-translational tyrosination and acetylation of tubulin, illustrating the complexity of CG-NAP\'s role in coordinating microtubule dynamics and stability in migrating T cells ([@B20]).

Prospects of Therapeutic Targeting of CG-NAP and Associated Challenges {#s5}
======================================================================

Immune-mediated diseases caused by T cell dysfunction are an increasing cause of mortality worldwide. While available therapeutic agents target T cell trafficking and immune hyperactivity, such treatment modalities are often accompanied by significant side effects. For example, while blocking LFA-1/ICAM-1 interaction has been proven to be effective in treating immune diseases, such as psoriasis ([@B120]), such immunosuppression can trigger the activation of JC-1 virus in the central nervous system leading to the development of fatal progressive multifocal leukoencephalopathy ([@B121], [@B122]). In prior studies, we have demonstrated that pre-activation through the LFA-1 pathway also alters the T cell programme, such that these stimulated T cells become refractory to TGFβ-mediated suppression and exhibit increased IL-17 secretion ([@B123]). Further studies are required to delineate whether specific interactions between CG-NAP and its docking partners may mediate specific migratory or secretory signals impacting on immune effector mechanisms. Fine-tuning of these interactions can provide functional selectivity and may offer exciting therapeutic approaches for a wide array of immune-mediated diseases.

One such fine-tuning strategy could be to alter a specific CG-NAP/kinase interaction by targeting a single protein-protein interaction. This could be achieved by either developing inhibitors against a specific kinase interaction in the CG-NAP interactome or by targeting CG-NAP/kinase interacting domain by blocking peptides ([@B124]). Although more likely to serve as a research tool, blocking peptides may assist in designing and developing small molecules targeting CG-NAP/kinase interactions, representing an interesting area of research and drug discovery. Further structural modeling of CG-NAP/kinase interactions should also identify suitable targets for small molecule inhibitors.

Targeting CG-NAP in its entirety would be challenging mainly because (i) this adaptor protein is expressed as several alternatively spliced transcripts and (ii) the degree of complexity of CG-NAP\'s involvement in multiple aspects of T cell signaling makes it difficult to elucidate each of their individual roles. One plausible strategy to understand the role of CG-NAP in T cell functioning would be to selectively displace interacting kinases and their subtypes from the CG-NAP docking platform. This would require the development of isoform-specific disruptors and other molecular tools to dissect individual pathway and CG-NAP/kinase interactions with high specificity. Exciting tools are available to silence individual gene in T lymphocytes that can be used to study functional involvement of specific interaction between CG-NAP and an individual kinase. These include the use of antisense GapmeR ([@B119]), siRNAs, gene correction and CRISPR-Cas9 editing techniques, which can be employed to overcome immune-mediated pathologies.

Conclusion {#s6}
==========

It is evident from the past two decades of research that CG-NAP regulates a plethora of biological processes by organizing supramolecular complexes and facilitating dynamic interactions between many different kinases and their substrates. In T cells, CG-NAP plays an important role in motility and participates in multiple interdependent pathways of T cell activation and effector functions. Thus, systematic studies are warranted to shed light on common or distinct binding partners and functions of CG-NAP and clarify to what extent CG-NAP/kinase interactions regulate T cell functions.

There is growing interest in developing protein-protein interaction disruptors, which would open new opportunities for therapeutic targeting of individual interactions between CG-NAP and specific kinases. A better understanding of CG-NAP/kinase interactions in T lymphocytes and their functional perturbations in immune response regulation is likely to lead to new frontiers in the treatment of T cell-mediated diseases.
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